Reply to Musher
TO THE EDITOR-We appreciate Musher's thoughtful comments to our study on antibody concentrations against the infecting serotype in children with invasive pneumococcal disease (IPD). In his letter, Musher suggests that the low antibody concentrations against the infecting serotype may be governed by unrecognized genetic factors [1] .
We agree that vaccine responses have a genetic component, and this is most likely to be true for pneumococcal polysaccharide vaccines (PPV) and pneumococcal conjugate vaccines (PCV). However, we do not think that this was a key contributor to the results of our study because the low antibody concentrations found in children vaccinated before and/or after IPD were specific to the infecting pneumococcal serotype [2] . The responses to the remaining serotypes in vaccinated children were not impaired. To our knowledge, there is no evidence for genetic mechanisms explaining serotype-specific responses to conjugate vaccines. In Musher's study on genetic regulation of responses to pneumococcal capsular polysaccharides (PPS) [3] , the responder status of offspring was associated with that of their parents, but this association was not serotype-specific. Consequently, the authors concluded that "responsiveness to PPS as a class of antigens seemed to be more clearly related to inheritance than did the response to any individual PPS antigen" [3] . Furthermore, 5 of 7 adults who initially responded poorly to PPV developed "excellent immunoglobulin G (IgG) responses" after immunization with PCV [3, 4] , which makes the results difficult to compare to our study involving children with IPD who received PCV only.
In our study, vaccination with PCV before and/or after IPD was associated with lower IgG concentrations specifically against the infecting serotype, but responses to other vaccine serotypes were unaffected. As this phenomenon initially clustered around the period following the introduction of the 7-valent PCV and was particularly associated with serotype 6B, which was the most prevalent serotype in carriage at the time, we proposed that nasopharyngeal carriage before or at the time of PCV in infancy might have led to the serotype-specific unresponsiveness observed. This is in line with several clinical trials reporting an association between nasopharyngeal carriage before or at the time of vaccination with PPV or PCV in infants or toddlers and lower serotype-specific post-vaccination responses to the carried serotype [5] [6] [7] [8] [9] . It is also possible that pneumococcal infection itself could have contributed to the lower IgG concentrations against the infecting serotype. It has been proposed that the observed serotype-specific unresponsiveness is due to depletion of the memory B-cell pool after exposure to a large pneumococcal capsular polysaccharide load following carriage or disease [10] . The generation of suppressor T cells could be another possible but unlikely explanation because human studies have not identified pneumococcal serotype-specific T cells [11] . Similarly, other mechanisms such as functional T-cell deficiency may explain lower overall-but not individual serotype-specific-antibody responses after conjugate vaccination [12] . Thus, a genetic basis for the observed serotypespecific unresponsiveness against the infecting serotype in PCV-immunized children with IPD seems unlikely. However, we can only speculate on possible immunological and/or environmental factors. This clearly requires further study.
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